Sytelgy

Class [005]
Gene therapy products, namely, genetically engineered tissues for transplant purposes; Gene therapy products, namely, recombinant adeno-associated virus (rAAV) vector for treating ocular diseases; Gene therapy products, namely, rAAV vector for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant nucleic acid for treating ocular diseases; Gene therapy products, namely, recombinant nucleic acid for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant DNA for treating ocular diseases; Gene therapy products, namely, recombinant DNA for treating Retinitis Pigmentosa; Gene therapy products, namely, rAAV for treating ocular diseases such as Leber congenital amaurosis (LCA), retinitis pigmentosa, enhance S-cone syndrome, Goldmann Favre syndrome, rod-cone dystrophy Bardet-Biedl Syndrome, Achromatopsia, Best Disease (vitelliform macular degeneration), Bardet-Biedl Syndrome, Choroideremia, Macular Degeneration, Stargardt Disease, X-Linked Retinoschisis (XLRS), X-Linked Retinitis Pigmentosa (XLRP), Usher Syndrome, cone-rod dystrophy, Dry-Age related macular degeneration, and wet-Age related macular degeneration